| New trends in cannabis potency in USA and Europe during the last decade (2008-2017) |
56 |
| A randomised controlled trial of vaporised Delta(9)-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects |
28 |
| Does regular cannabis use affect neuroanatomy? An updated systematic review and meta-analysis of structural neuroimaging studies |
24 |
| Cannabis and mental illness: a review |
20 |
| Antioxidant uric acid in treated and untreated subjects with major depressive disorder: a meta-analysis and meta-regression |
17 |
| Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis |
16 |
| How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review |
15 |
| Stigma as a barrier to recognizing personal mental illness and seeking help: a prospective study among untreated persons with mental illness |
15 |
| Neurobiology of the major psychoses: a translational perspective on brain structure and function-the FOR2107 consortium |
14 |
| Keap1-Nrf2 signaling pathway confers resilience versus susceptibility to inescapable electric stress |
13 |
| An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use |
12 |
| Sports psychiatry: mental health and mental disorders in athletes and exercise treatment of mental disorders |
12 |
| The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain |
11 |
| Age-related differences in the impact of cannabis use on the brain and cognition: a systematic review |
10 |
| Self-stigma as a barrier to recovery: a longitudinal study |
10 |
| Effect of transcranial direct current stimulation on decision making and cognitive flexibility in gambling disorder |
9 |
| It can't hurt, right? Adverse effects of psychotherapy in patients with depression |
9 |
| Self-disorders in schizophrenia-spectrum disorders: a 5-year follow-up study |
9 |
| The impact of cognitive insight, self-stigma, and medication compliance on the quality of life in patients with schizophrenia |
9 |
| Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms? |
9 |
| Oxidative stress in drug-na < ve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders |
9 |
| Mindfulness vs psychoeducation in adult ADHD: a randomized controlled trial |
9 |
| Chronobiological theories of mood disorder |
8 |
| Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia |
8 |
| Modifiable and non-modifiable factors associated with functional impairment during the inter-episodic periods of bipolar disorder |
8 |
| PsychotherapyPlus: augmentation of cognitive behavioral therapy (CBT) with prefrontal transcranial direct current stimulation (tDCS) in major depressive disorder-study design and methodology of a multicenter double-blind randomized placebo-controlled trial |
8 |
| Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort |
7 |
| Abnormal levels of vascular endothelial biomarkers in schizophrenia |
7 |
| A novel Seizure Quality Index based on ictal parameters for optimizing clinical decision making in electroconvulsive therapy. Part 1: development |
7 |
| Psychiatric comorbidity as a risk factor for mortality in people with anorexia nervosa |
7 |
| NMDA receptor subunits change in the prefrontal cortex of pure-opioid and multi-drug abusers: a post-mortem study |
7 |
| Neural correlates of instrumental responding in the context of alcohol-related cues index disorder severity and relapse risk |
7 |
| Is electroconvulsive therapy an evidence-based treatment for catatonia? A systematic review and meta-analysis |
7 |
| Reduced oligodendrocyte density in layer 5 of the prefrontal cortex in schizophrenia |
7 |
| Elemental fingerprinting of schizophrenia patient blood plasma before and after treatment with antipsychotics |
7 |
| Kynurenine pathway and white matter microstructure in bipolar disorder |
7 |
| Axonal myelin decrease in the splenium in major depressive disorder |
7 |
| ADHD modulates the course of delinquency: a 15-year follow-up study of young incarcerated man |
7 |
| Alterations in resting-state gamma activity in patients with schizophrenia: a high-density EEG study |
6 |
| Obsessive-compulsive symptoms and overall psychopathology in psychotic disorders: longitudinal assessment of patients and siblings |
6 |
| Prenatal alcohol use as a risk for attention-deficit/hyperactivity disorder |
6 |
| A novel seizure quality index based on ictal parameters for optimizing clinical decision-making in electroconvulsive therapy. Part 2: Validation |
6 |
| Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort |
6 |
| Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain |
6 |
| Bipolar spectrum in major depressive disorders |
6 |
| Depressive residual symptoms are associated with illness course characteristics in a sample of outpatients with bipolar disorder |
6 |
| Meta-analysis of physical activity and effects of social function and quality of life on the physical activity in patients with schizophrenia |
5 |
| Psychiatric comorbidity in alcohol use disorders: results from the German S3 guidelines |
5 |
| Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study |
5 |
| Course of clinical high-risk states for psychosis beyond conversion |
5 |
